Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that androsterone glucuronate (ADT-G) was the only androgenic metabolite sensitive to detecting differences between adult women with acne and controls, and its levels decreased with systemic treatment.

The authors concluded that plasma levels of 3α-diolG, ADTG, and DHTG in women with hyperandrogenic disorders primarily reflect adrenal androgen contributions rather than peripheral action, suggesting a potential index for treatment effectiveness.

In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.

Reduced androgens linked to kinky hair disorder and hair loss; 5a-reductase inhibitors may help.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

This review highlights the efficacy of transdermal testosterone therapy in improving sexual function in women with hypoactive sexual desire disorder, though approved formulations and long-term safety data are limited.

This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.

This narrative review highlights the critical role of intracrine hormone production in peripheral tissues, suggesting that continuous-release subcutaneous testosterone pellet therapy may offer a more effective symptom-driven approach for aging populations, though large-scale randomized controlled trials are needed for confirmation.

This review explores adult female acne, focusing on its multifactorial causes, treatment options, and impact on quality of life, but reports no new clinical results.

This study found that the enzyme encoded by Dgat1 acts as a retinol acyltransferase in murine epidermis, protecting against retinoid toxicity and alopecia by preventing retinol accumulation.

This article reviews studies showing AT-Grow as effective in treating benign prostatic disease due to its anti-androgen properties but reports no new findings on its effect on hair growth.

In this study, PGD2 was shown to increase testosterone production in human keratinocytes through reactive oxygen species, suggesting potential benefits of antioxidants like N-acetyl-cysteine for AGA patients.

This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.

This study found that testosterone promotes proliferation, migration, and invasion in human glioblastoma cell lines through its conversion into dihydrotestosterone, which can be inhibited by drugs blocking 5α-reductase activity.

This study found that testosterone may promote glioblastoma progression by being converted into dihydrotestosterone, which enhances cell proliferation, migration, and invasion in GBM cell lines.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This study found that TAZ promotes adipogenesis in goat adipose-derived mesenchymal stem cells by enhancing PI3K/AKT pathway activity, with overexpression boosting adipocyte formation and knockdown inhibiting it.

In this study, researchers presented a novel therapeutic approach for androgenetic alopecia combining AR-PROTAC degradation with regenerative strategies and evaluated the potential of GT20029 as a topical treatment, proposing a three-phase protocol and future research hypotheses.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

AGD1 is important for root hair development in Arabidopsis, working with phosphoinositide signaling and the actin cytoskeleton.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

This study developed a DPC cell line by introducing mutant CDK4, Cyclin D1, and TERT, making it a promising tool to study downstream signaling pathways activated by testosterone in androgenetic alopecia.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.

This article discusses hormonal mechanisms underlying androgenetic alopecia but does not report any new findings; it reviews the roles of dihydrotestosterone and available FDA-approved treatments.

This study found that prostaglandin D2 promotes androgen receptor and AKT signaling in human dermal papilla cells through the DP2 receptor, potentially contributing to androgenetic alopecia.

This study found that external application of DGD activates the Wnt/β-catenin signaling pathway, promoting hair follicle anagen phase entry, and is a more effective and safer treatment for androgenetic alopecia in mice compared to oral administration.

In this study, the disruption of Gh/tissue transglutaminase in mice did not affect viability but reduced thymocyte viability and fibroblast adhesion, suggesting its role in cell stabilization and extracellular matrix interactions.